Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $69.61M rose 95.5% year over year, behind the +320.2% change in trailing-twelve-month net income. Sequentially, it fell 10.8% from the prior quarter.

Context

  • Net income amounted to 2.4% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of $345.77M (+379.9%) for the fiscal year ending Dec 2026, a step up from the +197.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$69.61M-10.8% QoQ
Last fiscal yearDec 2025
$72.06M+197.5% YoY
LTMJun 2026
$215.32M+320.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+95.5%+339.6%+244.1 pp
1 year+197.5%+379.9%+182.3 pp
3-year CAGR—+94.3%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
72.06M USD
Year-over-year change
+197.5%
4-year CAGR
+61.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +320.2% is the 4th highest of 11, against a peer median of +40.3%.
  • Net income amounts to 6.9% of revenue for AMRX, versus a peer median of 10.0%.
AMRX Competitors
Net Income for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹27.72B INR-52.4%+0.0%8.4%
PRGOPerrigo Company plcLTM Jun 2026$2.12B USD+3115.5%+120.4%51.0%
BHCBausch Health Companies Inc.LTM Jun 2026$1.1B USD-2132.0%—10.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$709M USD+537.7%—4.1%
VTRSViatris Inc.LTM Jun 2026$410.7M USD-88.2%—2.8%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$356M USD+132.7%—26.7%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$215.32M USD+320.2%—6.9%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$90.09M USD+528.0%—9.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$79.23M USD-44.1%+2.4%11.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$8.6M USD-93.5%—1.3%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$7.4M USD+124.6%-20.3%17.6%
Peer median (excluding AMRX) —+40.3%+1.2%10.0%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income10.62M(254.79M)(48.72M)(73.88M)72.06M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
Deferred Income Tax00000
Stock-Based Compensation031.85M26.82M27.77M31.95M
Change in Working Capital(133.59M)(59.95M)(47.19M)(4.07M)(204.52M)
Accounts Receivables(16.31M)(79.07M)125.8M(162.16M)(120.57M)
Inventory(49.02M)(102.4M)(126.18M)(130.53M)(87.03M)
Accounts Payables(43.93M)109.57M(94.45M)235.14M21.32M
Other Working Capital(24.34M)11.95M47.64M53.48M(18.23M)
Other Non-Cash Items131.38M107.81M185.26M109.08M216.93M
Operating Cash Flow241.82M65.1M345.58M295.1M339.99M
Capital Expenditures(47.73M)(90.6M)(69.19M)(74.99M)(70.06M)
Acquisitions (Net)(141.54M)(84.71M)011.99M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.21M)(40.8M)(22.39M)(14.65M)(42.2M)
Investing Cash Flow(194.18M)(174.31M)(69.19M)(63M)(112.26M)
Debt Repayment(79.18M)(38.27M)22.65M(185.12M)26.27M
Common Stock Issued853K0001.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(59.8M)(68.35M)(235.23M)(26.67M)(59.76M)
Financing Cash Flow(138.12M)(106.62M)(212.57M)(211.79M)(31.53M)
Effect of Forex Changes102K(5.68M)65K(999K)(1.68M)
Net Change in Cash(90.38M)(221.51M)63.88M19.31M194.52M
Free Cash Flow194.09M(25.5M)276.39M220.11M269.93M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.